Clinical trialNCT03943875CompletedPhase 4Interventional

GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose

SponsorThe University of Texas Medical Branch, GalvestonEnrollment767EfficacyHuman Papilloma VirusImmunization

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The investigators are evaluating whether 15-26 year old males and females need a 3rd dose of the human papillomavirus (HPV) vaccine, or whether 2 doses provide similar protection as 3 doses from the 9 types of HPV that it protects against.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Abbey B Berenson, MD, PhD
University of Texas
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Texas Medical Branch
Galveston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

9-valent HPV vaccine, 2 dose efficacy9-valent HPV vaccine, 3 doses standard timing

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 17 Jun 2019
Primary completion: 13 Jan 2025
Completion: 13 Jan 2025
Last update posted: 16 Apr 2026
Registered enrollment: 767
Registry id: NCT03943875

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.